Bioptimus - Case Study
Sacha Dessaint Axel Lievre Victor Garreau Joan Thomas
A highly restrictive environment
A very favorable environment
A paradoxical environment
Massive public support from politicians and institutions France 2030 FrenchTech Next 40/120 Determination to compete with American giants
Major regulatory constraints Considered “high risk” Highly constrained in legal, economic, and environmental terms Natural barrier to entry
Business model: cost allocation
Long R&D cycles $76 million raised in Seed and Series A funding rounds
60% Calculation
30% Talents
10% Data
Recruitment of scientific talent Rare and highly qualified profiles
GPU Cloud Infrastructures
Access to clinical and biological data
The societal challenge
Precision medicine
Mistrust of AI
Aging population Increasing complexity of diseases Rising demand Major strategic lever
Persistent mistrust of AI Black boxes Real need for clear results by biologists and clinicians
Multi-scale foundation models
Unique technology
Environmental impact
Distinction
Multi-scale strategy Differentiation with tools such as AlphaFold More fragmented competing solution
Biological foundation models H-optimus models Multi-level data integration Enables a systemic approach to living organism
Technological advancement with a significant environmental cost Model training Need to anticipate future European standards
Intense and multifaceted competition
Specialized actors
Insilico Medicine BenevolentAI Recursion Pharmaceuticals Iktos Brightseed
Tense competitive structure
High rivalry Very strong bargaining power of suppliers NVIDIA and Owkin Significant buyer power ROI requirements, regulatory compliance, and clinical evidence
Indirect pressure
Tech giants Google DeepMind IBM Watson Health
Addressable segment
A B2B market
Addressable market representing $12 to $15 billion Realistic penetration of 1 to 2% in 3 to 5 years Potential revenue generation between $120 and $300 million per year Viability of the model
Very high added value A market estimated at between $50 billion and $60 billion Annual growth exceeding 25%
A high-value niche market
The various internal components
Robust strategic foundation
A highly restrictive environment
Internal risk
Risk of strategic dispersion Identity as a cutting-edge research laboratory International commercial player Continuous gap analysis
Responses to VRIO criteria Accelerated drug discovery Exclusive access to Owkin data Hybrid AI/biology expertise Tailored organization
Alignment according to the McKinsey 7S model Strengthening of the platform project and its consistency
Marketing strategy
Key recruitment
Targets and strategy
Structuring of the product offering Scientific credibility Scaling of infrastructure and partnerships Conquest of the US market Partnership with Proscia Access to established hospital networks
Big Pharma R&D decision-makers Dr. Sophie Lebrun H-optimus-0 open source Accelerate adoptionBecome an industry standard Gradually monetize via H-optimus-1
10
Next steps
Economic model
Financing commercial expansion in the United States Securing more sovereign computing capabilities Specialized European and US institutional funds Creating specialized subsidiaries without diluting parent company capital Using carbon-free nuclear energy as a CSR argument
Licenses Research partnerships Royalties Break-even achieved upon signing at least five major contracts with Big Pharma
Financial model and outlook
11
Vision 2024–2028
Objective: transform Bioptimus from a DeepTech startup into a leading global biological platform. Three pillars: - Secure critical resources. - Verticalize by pathology. - Structure a scalable platform model.
Scarce data, elite team, public support, and long-term vision. Success depends on its ability to become an industry standard that is transparent, sovereign, and profitable.
Thank you for your attention !
Bioptimus
Sorio51
Created on February 9, 2026
Start designing with a free template
Discover more than 1500 professional designs like these:
View
Smart Presentation
View
Practical Presentation
View
Essential Presentation
View
Akihabara Presentation
View
Flow Presentation
View
Dynamic Visual Presentation
View
Pastel Color Presentation
Explore all templates
Transcript
Bioptimus - Case Study
Sacha Dessaint Axel Lievre Victor Garreau Joan Thomas
A highly restrictive environment
A very favorable environment
A paradoxical environment
Massive public support from politicians and institutions France 2030 FrenchTech Next 40/120 Determination to compete with American giants
Major regulatory constraints Considered “high risk” Highly constrained in legal, economic, and environmental terms Natural barrier to entry
Business model: cost allocation
Long R&D cycles $76 million raised in Seed and Series A funding rounds
60% Calculation
30% Talents
10% Data
Recruitment of scientific talent Rare and highly qualified profiles
GPU Cloud Infrastructures
Access to clinical and biological data
The societal challenge
Precision medicine
Mistrust of AI
Aging population Increasing complexity of diseases Rising demand Major strategic lever
Persistent mistrust of AI Black boxes Real need for clear results by biologists and clinicians
Multi-scale foundation models
Unique technology
Environmental impact
Distinction
Multi-scale strategy Differentiation with tools such as AlphaFold More fragmented competing solution
Biological foundation models H-optimus models Multi-level data integration Enables a systemic approach to living organism
Technological advancement with a significant environmental cost Model training Need to anticipate future European standards
Intense and multifaceted competition
Specialized actors
Insilico Medicine BenevolentAI Recursion Pharmaceuticals Iktos Brightseed
Tense competitive structure
High rivalry Very strong bargaining power of suppliers NVIDIA and Owkin Significant buyer power ROI requirements, regulatory compliance, and clinical evidence
Indirect pressure
Tech giants Google DeepMind IBM Watson Health
Addressable segment
A B2B market
Addressable market representing $12 to $15 billion Realistic penetration of 1 to 2% in 3 to 5 years Potential revenue generation between $120 and $300 million per year Viability of the model
Very high added value A market estimated at between $50 billion and $60 billion Annual growth exceeding 25%
A high-value niche market
The various internal components
Robust strategic foundation
A highly restrictive environment
Internal risk
Risk of strategic dispersion Identity as a cutting-edge research laboratory International commercial player Continuous gap analysis
Responses to VRIO criteria Accelerated drug discovery Exclusive access to Owkin data Hybrid AI/biology expertise Tailored organization
Alignment according to the McKinsey 7S model Strengthening of the platform project and its consistency
Marketing strategy
Key recruitment
Targets and strategy
Structuring of the product offering Scientific credibility Scaling of infrastructure and partnerships Conquest of the US market Partnership with Proscia Access to established hospital networks
Big Pharma R&D decision-makers Dr. Sophie Lebrun H-optimus-0 open source Accelerate adoptionBecome an industry standard Gradually monetize via H-optimus-1
10
Next steps
Economic model
Financing commercial expansion in the United States Securing more sovereign computing capabilities Specialized European and US institutional funds Creating specialized subsidiaries without diluting parent company capital Using carbon-free nuclear energy as a CSR argument
Licenses Research partnerships Royalties Break-even achieved upon signing at least five major contracts with Big Pharma
Financial model and outlook
11
Vision 2024–2028
Objective: transform Bioptimus from a DeepTech startup into a leading global biological platform. Three pillars: - Secure critical resources. - Verticalize by pathology. - Structure a scalable platform model.
Scarce data, elite team, public support, and long-term vision. Success depends on its ability to become an industry standard that is transparent, sovereign, and profitable.
Thank you for your attention !